Table 2.
Baseline clinical characteristics of RA patients.
| Variables | Mean ± SD | Min | Median | Max |
|---|---|---|---|---|
| Scores of joints | 3.38 ± 1.86 | 0 | 4 | 5 |
| Scores of X- ray | 2.71 ± 1.20 | 0 | 3 | 4 |
| Pain (VAS) | 3.36 ± 1.17 | 0 | 2 | 9 |
| PGA (VAS) | 4.69 ± 2.58 | 0 | 5 | 10 |
| EGA (VAS) | 3.56 ± 2.32 | 0 | 3 | 8 |
| HAQ | 0.77 ± 0.36 | 0 | 0.51 | 2.75 |
| DAS28 | 4.01 ± 1.83 | 0.78 | 4.00 | 7.6 |
| ESR (mm/h) | 40.67 ± 34.28 | 2 | 28 | 140 |
| CRP (mg/L) | 46.69 ± 26.31 | 0 | 4.9 | 180.08 |
| RF (IU/mL) | 138.99 ± 113.11 | 9 | 115 | 492.8 |
| Anti-CCP (IU/mL) | 581.14 ± 489.39 | 6 | 564.5 | 1645 |
Clinical variables and laboratory parameters in RA patients were abnormal.
Anti-CCP anti-cyclic citrullinated peptide, CRP C-reactive protein, DAS28 disease activity score in 28 joints, EGA evaluator global assessment of disease activity, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, PGA patient’s global assessment of disease activity, RF rheumatoid factor, VAS visual analogue scale.